Michigan is currently home to 2254 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Henry Ford Health System, Bingham Farms, Michigan
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
Reduce Emotional Symptoms of Insomnia With SleepTreatment
NCT03724305
Recruiting
The purpose of this research is to test whether Mindfulness-Based Therapy for Insomnia (MBTI) significantly reduces symptoms of insomnia and cognitive arousal in patients with treatment-resistant insomnia.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/17/2022
Locations: Henry Ford Health System - Columbus, Novi, Michigan
Conditions: Insomnia, Rumination
Register for Updates
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
NCT04485260
Recruiting
This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary objective of the study is to determine a recommended phase 2 dose (RP2D) of KRT 232 in combination with ruxolitinib.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
05/05/2022
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Myelofibrosis
Register for Updates
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
NCT05205070
Recruiting
Efficacy and safety of rosnilimab (ANB030) in subjects with moderate-to-severe Alopecia Areata
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/03/2022
Locations: Site 10-117, Clarkston, Michigan
Conditions: Alopecia Areata
Register for Updates
Value For Veterans (V4V)
NCT05026684
Recruiting
The COVID-19 pandemic has transformed the delivery of ambulatory care in the US. One of the most notable changes to ambulatory care practice has been the rapid expansion of telemedicine services. Such expansion sought to preserve access to necessary care for patients while protecting them and their clinicians from undue risk of exposure to COVID-19. This multiphase, Veteran-centered approach to developing and evaluating a novel behavioral intervention to provide full cost transparency to Vetera... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/28/2022
Locations: VA Ann Arbor Healthcare System, Ann Arbor, Michigan
Conditions: Delivery of Health Care
Register for Updates
Clinical and Genetic Analysis of ROP
NCT04420156
Recruiting
Retinopathy of Prematurity (ROP) is a vascular disease affecting the retinas (back of the eye) of low birth weight infants. Although it can be treated effectively if diagnosed early, it continues to be a leading cause of childhood blindness in the United States and throughout the world. The investigators feel that this study will result in specific knowledge discovery about ROP, as well as general knowledge about how image-based data and genetic data can be combined to better understand clinical... Read More
Gender:
All
Ages:
1 year and below
Trial Updated:
04/18/2022
Locations: William Beaumont Hospital, Royal Oak, Michigan
Conditions: Retinopathy of Prematurity
Register for Updates
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
NCT03540771
Recruiting
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services) Primary Outcome: The change in quality of life from baseline to 3 months post enrollment as assessed by FACT-... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/05/2022
Locations: University of Michigan Medical Center, Ann Arbor, Michigan
Conditions: End Stage Liver Disease
Register for Updates
Efficacy of the Apollo System for Children With ADHD
NCT05308706
Recruiting
To determine the extent to which the Apollo System is effective in reducing symptomatology associated with ADHD.
Gender:
All
Ages:
Between 8 years and 17 years
Trial Updated:
03/24/2022
Locations: Department of Kinesiology, East Lansing, Michigan
Conditions: Attention Deficit Disorder With Hyperactivity
Register for Updates
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
NCT02061436
Recruiting
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly being performed in patients with advanced coronary artery disease, but there is limited information on the techniques utilized and the procedural outcomes. The goal of this multicenter, investigator initiated registry is to collect information on treatment strategies and outcomes of consecutive patients undergoing CTO PCI among various participating centers. The information collected will be used to deter... Read More
Gender:
All
Ages:
All
Trial Updated:
03/08/2022
Locations: Henry Ford Medical Center, Detroit, Michigan
Conditions: Coronary Artery Disease
Register for Updates
Efficacy of Local Anesthetic Through Continuous Infusion
NCT04173312
Recruiting
Efficacy of using continuous infusion of local anesthetic for post operative pain control following laparotomy.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/22/2022
Locations: Ascension Genesys Hospital, Grand Blanc, Michigan
Conditions: Pain Control
Register for Updates
PEN-866 in Patients With Advanced Solid Malignancies
NCT03221400
Recruiting
Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2022
Locations: Henry Ford, Detroit, Michigan
Conditions: Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
Register for Updates
FastThread Interference Screws
NCT04689061
Recruiting
Surgery using the Arthrex PEEK or Biocomposite FastThread Interference Screw for ACL or PCL (PCL at US sites only, Biocomposite screw PCL only) repair or reconstruction.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/15/2022
Locations: Anderson Sports Medicine, Bingham Farms, Michigan
Conditions: ACL Injury
Register for Updates